Good MorningEquities markets fell on Wednesday as bond yields come back into focus. The yield on the 10-year Treasury rose more than 5 basis points to close at the second-highest level in over a year as investors continue to bet on rising inflation. The rise in the bond yield implies the FOMC will have to alter policy sooner rather than later and that could be a bad thing for the stock market. A more hawkish FOMC outlook could crimp the growth outlook and would likely spark profit-taking if not a deeper correction.
In economic news, both the ISM Services index and the ADP Employment figures were below expectation. The ADP figure showed jobs were gained in February but a lower rate than was expected. The ISM data shows the services sector continues to grow but also at a slower rate than was expected.
Featured: Sell these "safe" blue chips immediately (Ad) 
|
Technology | |
Lately, it has often been the case that when a stock takes a downturn it has proven to be a good buy opportunity. However, the strategy does not always hold true as things can always get worse before they get better.
Sometimes a company simply has limited growth prospects, fundamental flaws, or h... Read the Full Story |
|
From Our Partners | | Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief.
It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live. | | Watch the full story and see the verified track record for yourself |
|
Markets | |
Can you think of an industry that was hit harder during the onset of the pandemic more than resorts & casinos? Casino stocks were pummeled throughout 2020 as they reported sharp declines in revenue and earnings while people were stuck at home and practicing social distancing. It was hard for t... Read the Full Story |
|
Consumer Discretionary | |
For anyone who thought the mall-facing retailer was in a state of hopeless decline, American Eagle (NYSE:AEO) has a real surprise for you. Actually, it has two surprises: beats in both earnings and revenue. It's been a rough year for the mall-facing retailer, but there are signs that it's coming b... Read the Full Story |
|
From Our Partners | | Moderna's stock doubled in a single day after its cancer vaccine hit key Phase 3 goals, and Merck jumped too. But according to a former Steve Cohen fund manager, the next big opportunity is not Moderna or Merck.
It is a different kind of company tied to a technology already backed by Elon Musk, Sam Altman, Jeff Bezos, and Peter Thiel. Nvidia's Jensen Huang says it will have a dramatic impact on daily life, while Anthropic's CEO believes it could unlock a century of medical progress in just ten years.
Nature Magazine estimates its potential value at $367 trillion globally, and it is already rolling out across the United States. | | Click here to learn about this new era of medical technology |
|
Markets | |
Ethereum Enters Bear Market! Oh No!
After correcting more than 36% and entering a deep bear-market many traders and investors are wondering if Ethereum’s (ETH) run is over. Well, we’re here to tell you there are fundamental forces at play that suggest Ethereum’s bull market is f... Read the Full Story |
|
Finance | | The folks over at insurance tech name Lemonade (NYSE: LMND) are quickly learning that what goes up, almost always comes down. Despite jumping more than 300% from last November through the start of January, shares have since lost their mojo and have been sliding hard. A 7% drop in Wednesday’s s... Read the Full Story |
|
From Our Partners | | Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required.
Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away. | | Discover the gold income fund before the next payout date |
|
Consumer Discretionary | |
Kohl’s (NYSE: KSS), Target (NYSE: TGT), Abercrombie & Fitch (NYSE: ANF) and AutoZone (NYSE: AZO) are among high profile retailers reporting earnings this week.
The retail sector has been on a roller coaster ride. Even before the pandemic, the situation looked dire for brick and mortar. ... Read the Full Story |
|
Markets | |
One of the big advantages of growth investing is the potential for market-beating returns. Choose wisely and you can be rewarded with outsized gains when compared to the overall market. However, investors should also keep in mind that growth stocks can underperform the market in a big way when sto... Read the Full Story |
|
Consumer Staples | |
The recent S&P 500 pullback off its record high has been caused by a few factors. Concerns about potential inflation, rising bond yields, and ongoing pandemic uncertainty sparked a late-February swoon in the market.
While the downturn has thus far been mild and may ultimately amount to yet an... Read the Full Story |
|
Consumer Discretionary | | Overpriced Wendy’s Moves Lower
There are a growing number of companies not living up to their expectations and Wendy’s (NASDAQ:WEN) is one of them. The problem, at least for Wendy’s, could be a good one, however, and one that might well lead to a great buying opportunity. You see... Read the Full Story |
|
Technology | | Amberella Is At The Forefront Of Computer Vision
We started getting bullish on Ambarella (NASDAQ:AMBA) over the past year for several reasons including 5G, the IoT, and EVs all of which rely on semiconductors and more and more heavily on light-sensing, imagery, and vision technology. Ambarella is t... Read the Full Story |
|
The Early Bird Stock Of The Day Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania. | | View Today's Stock Pick |
|
